Atherosclerosis
Volume 182, Issue 1 , Pages 87-95 , September 2005

Roxithromycin is an inhibitor of human coronary artery smooth muscle cells proliferation: a potential ability to prevent coronary heart disease

  • Hirofumi Tomita

      Affiliations

    • The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
    • ,
  • Tomohiro Osanai

      Affiliations

    • The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
    • ,
  • Tsutomu Toki

      Affiliations

    • Department of Pediatrics, Hirosaki University School of Medicine, Hirosaki, Japan
    • ,
  • Naotaka Maeda

      Affiliations

    • The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
    • ,
  • Reiichi Murakami

      Affiliations

    • The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
    • ,
  • Zhaoning Chen

      Affiliations

    • The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
    • ,
  • Hideaki Yamabe

      Affiliations

    • The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
    • ,
  • Hiroshi Osawa

      Affiliations

    • The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
    • ,
  • Minoru Yasujima

      Affiliations

    • Department of Laboratory Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
    • ,
  • Ken Okumura

      Affiliations

    • The Second Department of Internal Medicine, Hirosaki University School of Medicine, Hirosaki, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 172 39 5057; fax: +81 172 35 9190.

Received 29 September 2004 ,Revised 28 January 2005 ,Accepted 9 February 2005.

References 

  1. Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosclerosis—what we know and what we don’t. Clin Microbiol Infect. 2002;8:2–13
  2. Saikku P, Leinonen M, Mattila K, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet. 1988;2:983–986
  3. Gupta S, Leatham EW, Carrington D, et al. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation. 1997;96:404–407
  4. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. For the ROXIS study group. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet. 1997;350:404–407
  5. Gurfinkel E, Bozovich G, Beck E, et al. For the ROXIS study group. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS study. Eur Heart J. 1999;20:121–127
  6. Neumann F, Kastrati A, Miethke T, et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet. 2001;357:2085–2089
  7. Stone AFM, Mendall MA, Kaski J-C, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation. 2002;106:1219–1223
  8. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  9. Andres V. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential. Cardiovasc Res. 2004;63:11–21
  10. Monaco C, Paleolog E. Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res. 2004;61:671–682
  11. Ghosh S, May MJ, Kopp EB. NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol. 1998;16:225–260
  12. Obata H, Biro S, Arima N, et al. NF-κB is induced in the nuclei of cultured rat aortic smooth muscle cells by stimulation of various growth factors. Biochem Biophys Res Commun. 1996;224:27–32
  13. Bellas RE, Lee JS, Sonenshein GE. Expression of a constitutive NF-κB-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells. J Clin Invest. 1995;96:2521–2527
  14. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell. 1995;81:323–330
  15. Morgan DO. Principles of CDK regulation. Nature. 1995;374:131–134
  16. Puri SK, Lassman HB. Roxithromycin: a pharmacokinetic review of a macrolide. J Antimicrob Chemother. 1987;20(Suppl B):89–100
  17. Goodrich DW, Wang NP, Qian YW, Lee EY, Lee WH. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell. 1991;67:293–302
  18. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science. 1996;272:877–880
  19. Tanner FC, Boehm M, Akyurek LM, et al. Differential effects of the cyclin-dependent kinase inhibitors p27Kip1, p21Cip1, and p16Ink4 on vascular smooth muscle cell proliferation. Circulation. 2000;101:2022–2025
  20. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol. 1999;19:5785–5799
  21. Brand K, Page S, Rogler G, et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715–1722
  22. Cercek B, Yamashita M, Dimayuga P, et al. Nuclear factor-κB activity and arterial response to balloon injury. Atherosclerosis. 1997;131:59–66
  23. Marra DE, Simoncini T, Liao JK. Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21Waf1 and p27Kip1. Circulation. 2000;102:2124–2130
  24. Breuss JM, Cejna M, Bergmeister H, et al. Activation of nuclear factor-κB significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation. 2002;105:633–638
  25. Yoshimura S, Morishita R, Hayashi K, et al. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element ‘decoy’ of nuclear factor-κB binding site as a novel molecular strategy. Gene Ther. 2001;8:1635–1642
  26. Zahn R, Schneider S, Frilling B, et al. Working group of Leading Hospital Cardiologists. Antibiotic therapy after acute myocardial infarction: a prospective randomized study. Circulation. 2003;107:1253–1259
  27. Cercek B, Shah PK, Noc M, et al. AZACS Investigators. Effect of short-term treatment with azithromycin on recurrent ischaemic events in patients with acute coronary syndrome in the Azithromycin in Acute Coronary Syndrome (AZACS) trial: a randomised controlled trial. Lancet. 2003;361:809–813
  28. Sinisalo J, Mattila K, Valtonen V, et al. For the clarithromycin in acute coronary syndrome patients in Finland (CLARIFY) study group. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-Q-wave coronary syndrome. Circulation. 2002;105:1555–1560
  29. O’Connor CM, Dunne MW, Pfeffer MA, et al. Investigators in the WIZARD Study. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA. 2003;290:1459–1466

PII: S0021-9150(05)00128-0

doi: 10.1016/j.atherosclerosis.2005.02.007

Atherosclerosis
Volume 182, Issue 1 , Pages 87-95 , September 2005

Article Tools

* Image Usage & Resolution